Detalhe da pesquisa
1.
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Rheumatol Ther
; 7(3): 553-580, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32506317
2.
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
RMD Open
; 5(1): e000806, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30713721
3.
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
RMD Open
; 5(1): e000808, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30713722